Schizophrenia is a complex and unpredictable mental disorder which affects several domains of cognition and behaviour. It is a heterogeneous illness characterised by positive, negative, and cognitive symptoms, often accompanied by signs of depression. In this tutorial review, we discuss recent progress in understanding the target sites and mechanisms of action of second-generation antipsychotic drugs. Progress in identifying and defining target sites has been accelerated recently by advances in neuroscience, and newly developed agents that regulate signalling by the main excitatory neurotransmitters in the brain are surveyed. Examples of novel molecules for the treatment of schizophrenia in preclinical and clinical development and their industrial sponsors are highlighted.

中文翻译：

---

精神分裂症：药物设计的合成策略和最新进展

精神分裂症是一种复杂且不可预测的精神疾病，影响认知和行为的多个领域。这是一种异质性疾病，以阳性、阴性和认知症状为特征，通常伴有抑郁症状。在本教程综述中，我们讨论了了解第二代抗精神病药物的靶位点和作用机制的最新进展。最近，神经科学的进步加速了识别和定义靶点的进展，并且对调节大脑中主要兴奋性神经递质信号传导的新开发药物进行了调查。重点介绍了临床前和临床开发中用于治疗精神分裂症的新型分子及其工业赞助商的例子。